secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116942
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco appoints Stacey Ma to board; board expands to 15 members
---------------------------------------------------------------

- Ma appointed effective Nov 11, 2024; board increased from 14 to 15 directors.
- Ma will serve on Innovation, Science and Technology Committee.
- Ma is EVP of Pharmaceutical Development and Manufacturing at Gilead Sciences.
- Her expertise in CMC and drug development supports Elanco's IPP strategy.
- No related party transactions or arrangements in her appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465924116942/0001104659-24-116942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465924116942/tm2428235d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer